Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine-Reference-Cited by-同舟云学术

Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine

Published:2019-02-14 Issue:10 Volume:27 Page:3869-3875
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Vera Jesus^ORCID,Paludo Jonas,Kottschade Lisa,Brandt Jessica,Yan Yiyi,Block Matthew,McWilliams Robert,Dronca Roxana,Loprinzi Charles,Grothey Axel,Markovic Svetomir N.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-019-4654-2.pdf

Reference19 articles.

1. Schreuer M, Jansen Y, Planken S et al (2017) Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF V600−mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol 18:464–472

2. Lai X, Friedman A (2017) Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model. BMC Syst Biol 11:70

3. Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS (2013) Paradoxical oncogenesis–the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 10:390–399

4. Menzies AM, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante JR, Kim KB, Gonzalez R, Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, Aktan G, Ouellet D, Jin F, Long GV, Daud A (2015) Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Ann Oncol 26:415–421

5. Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM (2017) Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377:1813–1823

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune micro-environment analysis and drug screening for ovarian endometriosis;Genes & Genomics;2024-05-22

2. A distinct four-value blood signature of pyrexia under combination therapy of malignant melanoma with dabrafenib and trametinib evidenced by an algorithm-defined pyrexia score;PLOS ONE;2022-08-25

3. A distinct four-value blood signature of pyrexia under combination therapy of malignant melanoma with BRAF/MEK-inhibitors evidenced by an algorithm-defined pyrexia score;2022-04-02

4. Extreme elevation of acute phase reactants and shock secondary to dabrafenib–trametinib;Melanoma Research;2021-03-18

5. Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report;Pteridines;2020-01-01